EGFR and lung adenocarcinoma: A patient with <i>EGFR</i> L858R lung adenocarcinoma developed disease progression after 72.7 months of gefitinib therapy; rebiopsy was done, and next-generation sequencing showed the disappearance of the previous <i>EGFR</i> mutations.